Veraxa Biotech Holding AG (VRXA) Cash & Equivalents (2024 - 2025)
Veraxa Biotech Holding AG's (VRXA) quarterly Cash & Equivalents came in at $126368.1 in Q4 2025, down 97.94% year-on-year from $6.1 million in Q4 2024, and down 97.94% on a QoQ basis from $6.1 million in Q4 2024.
Veraxa Biotech Holding AG (VRXA) Cash & Equivalents (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXA) has 2 years of Cash & Equivalents data on file, last reported at $126368.1 in Q4 2025.
- On a quarterly basis, Cash & Equivalents fell 97.94% year-over-year to $126368.1 in Q4 2025; TTM through Dec 2025 was $126368.1, a 97.94% decrease from a year earlier, with the FY2025 full-year figure at $126368.1, down 97.94% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $126368.1, down from $6.1 million in the prior quarter.
- Over the last five years, Cash & Equivalents for VRXA reached as high as $6.1 million in Q4 2024 and fell as low as $126368.1 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126,368.15 |
| Dec 31, 2024 | 6.12 Mn |